Basic Information
| LncRNA/CircRNA Name | HOXA11-AS |
| Synonyms | NA |
| Region | GRCh38_7:27184518-27189293 |
| Ensemble | ENSG00000240990 |
| Refseq | NR_002795 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | apoptosis | Drug | Cisplatin | |
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | lung adenocarcinoma |
| ICD-0-3 | C34 |
| Methods | qPCR, Western blot, RIP, Dual luciferase reporter assay |
| Sample | cell lines (A549, H157, HEK-293T) |
| Expression Pattern | up-regulated |
| Function Description | The expression of HOXA11-AS was much stronger in cisplatin-resistant LUAD cells. patients with high expression of HOXA11-AS had shorter survival time. knockdown of HOXA11-AS caused positive changes in cell activities of LUAD. For example, cell proliferation and migration were weakened, the epithelial mesenchymal transition process was reversed, and apoptosis was induced. rescue assays were applied to demonstrate the ceRNA pattern consisting of HOXA11-AS, miR-454-3p and Stat3. |
| Pubmed ID | 30099826 |
| Year | 2018 |
| Title | LncRNA HOXA11-AS drives cisplatin resistance of human LUAD cells via modulating miR-454-3p/Stat3. |
External Links
| Links for HOXA11-AS | GenBank HGNC NONCODE |
| Links for lung adenocarcinoma | OMIM COSMIC |